28 June 2016
Stans, Switzerland, June 28, 2016
THERAMetrics holding AG (the “Company”) announces today that it expects its business combination with Relief Therapeutics SA (Relief) to be completed by mid-July 2016.
The Company, the shareholders of Relief Therapeutics SA (the “Relief Shareholders”) and GEM Global Yield Fund LLC S.C.S (“GEM Fund”) entered into an amendment to the original agreement, dated 19 December 2015, allowing more time for the Relief Shareholders to meet a condition precedent to the closing. At the same time, GEM Fund has committed to provide THERAMetrics with approx. CHF 2 million in cash by August 25, 2016. This commitment replaces GEM Fund’s previous commitment to provide such funds directly to Relief Therapeutics SA
THERAMetrics holding AG is a drug development company with a portfolio of drug candidates focussing on clinical stage projects of natural human origins. The company is listed on the SIX Swiss Exchange under the symbol TMX and is headquartered in Stans, Switzerland.
Relief Therapeutics SA is a clinical stage biotechnology company incorporated in May 2013 by Gaël Hédou, Michel Dreano and Yves Sagot, former Merck Serono employees. The mission of the company is to develop innovative treatments to address high unmet medical needs. In particular, the most advanced program aims at providing a cure for the debilitating affections that are associated with degeneration of the peripheral nervous system (neuropathy).
Global Emerging Markets was founded in 1991. GEM is a USD 3.4 billion investment group having completed 365 transactions in 65 countries. The firm is an alternative investment group that manages a diverse set of investment vehicles across the world. GEM’s funds include: CITIC-GEM Fund, Kinderhook, GEM Global Yield Fund, GEM India and VC Bank/GEM Mena Fund*.
(*GEM exited both its LP and GP stakes in Q1 2010.)
Dr. Raghuram Selvaraju
T. +41 (0)44 723 59 59
Relief Therapeutics SA
Chief Executive Officer
Warren P. Baker
T. +33 1 53 53 20 10
This communication expressly or implicitly contains certain forward-looking statements concerning THERAMetrics holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of THERAMetrics holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. THERAMetrics holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.